Drug Trial Radar · NCT07331194
Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Oct 28, 2025
Primary completion
Nov 28, 2025
Study completion Feb 2, 2026
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Jan 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Two formulations containing the same active pharmaceutical ingredient are considered bioequivalent if their relative bioavailability (rate and extent of drug absorption) falls within acceptable predetermined limits after administration at the same molar dose. Formulations with bioequivalence are considered to act comparably in vivo, i.e., similar in terms of safety and efficacy. This study aims to evaluate the pharmacokinetic (PK) profile and bioequivalence of the original and modified formulations of HMPL-523 acetate tablets in healthy participants to bridge the safety and efficacy of the modified formulation of HMPL 523 acetate tablets in humans.
Conditions
- Healthy
Interventions
HMPL-523 Acetate Tablets (Test Formulation)Drug
The trial participants were administered the drug on the first day of each cycle. dose 300mg
HMPL-523 Acetate Tablets (Reference Formulation)Drug
The trial participants were administered the drug on the first day of each cycle. dose 300mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parametersTime frame: up to two months
- PK parametersTime frame: up to two months
- PK parametersTime frame: up to two months
- PK parametersTime frame: up to two months
- PK parametersTime frame: up to two months
- The bioequivalence of two different drug product formulations of HMPL 523 acetate tabletsTime frame: up to two months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.